|
|
|
17.12.25 - 23:30
|
Afya Announces Changes to Its Board of Directors (Business Wire)
|
|
|
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, announced today that Mrs. Maria Tereza Azevedo notified the Company of her intent to resign as a member of the Board of Directors of the Company, effective as of December 31, 2025. Afya thanks Maria Tereza for her dedication and meaningful contributions to the Board and wishes her continued success in her future endeavors.
Afya's Board of Directors is composed of two co-chairmen - one representing Bertelsmann SE&Co. KGaA, and one representing the Esteves family -, one more member of the Esteves family, two more members of Bertelsmann SE&Co. KGaA, and four independent members, resulting in a diversity of skills and experience to enhance Afya's decision-making:
BOARD OF DIRECTORS
Name
Office
Nicolau Carvalho Esteves
Co-Chairman of the Board
Kay Krafft
Co-Chairman of the Board
Benedikt Dalkmann
Director
Chr...
|
|
|
|
|
|
|
|
|
13.11.25 - 03:15
|
Afya (AFYA) Q3 Earnings Beat Estimates (Zacks)
|
|
|
Afya (AFYA) delivered earnings and revenue surprises of +18.75% and -0.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...
|
|
|
|
|
13.11.25 - 00:18
|
Afya Limited Announces Third Quarter and Nine Months 2025 Financial Results (Business Wire)
|
|
|
Impressive Adjusted EBITDA Margin Expansion and Cash Generation
Full Year 2025 Guidance ReaffirmedBELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and nine-month period, which ended September 30, 2025 (third quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS).
Third Quarter 2025 Highlights
3Q25 Revenue increased 10.4% YoY to R$928.5 million. Revenue excluding acquisitions increased 10.1%, reaching R$926.2 million.
3Q25 Adjusted EBITDA increased 14.6% YoY, reaching R$398.9 million, with an Adjusted EBITDA Margin of 43.0%. Adjusted EBITDA Margin increased 160 bps YoY. Adjusted EBITDA excluding acquisitions grew 15.2%, reaching R$400.7 million, with an Adjusted EBITDA Margin of 43.3%.
3Q25 Net...
|
|
|
22.10.25 - 23:03
|
Repurchase of the Series A Perpetual Convertible Preferred Shares and Repayment of Afya Participações S.A. Debentures (Business Wire)
|
|
|
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, announced today that it has entered into a Share Repurchase Agreement with SBLA Holdco LLC, an affiliate of Softbank, to repurchase all 150,000 Series A Perpetual Convertible Preferred Shares of a nominal or par value of US$0.00005 each in the capital of the Company (the "Series A Preferred Shares") for an aggregate purchase price of R$831.6 million. The transaction is expected to close on November 3, 2025.
On April 26, 2021, the Company issued and sold 150,000 Series A Preferred Shares, equivalent to US$150.0 million in Reais, to Softbank. Afya intends to cancel all Series A Preferred Shares upon completion of the repurchase.
Afya also announced today that it has repaid in full on October 22, 2025, the R$500.0 million aggregate amount outstanding related to the first issuance of debentures by Af...
|
|
|
10.10.25 - 01:30
|
Issuance of Debentures (Business Wire)
|
|
|
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, announced today that its wholly owned subsidiary Afya Participações S.A. (“Afya Brazil”), has approved today the first issuance of book-entry commercial notes, in two series, for private placement, (the “Commercial Notes”), to be sold to Opea Securitizadora S.A. (“Opea”), a Brazilian securitization corporation pursuant to Section 45 of Brazilian Law No. 14,195/2021, as amended. Opea will issue a debenture backed by the Commercial Notes on the same terms and conditions.
The aggregate principal amount of the Commercial Notes is R$1,500.0 million, divided into two series, the first of which in the aggregate amount of R$500.0 million (the “First Series”) and the second in the aggregate amount of R$1,000million (the “Second Series”). The Commercial Notes are intended to be issued on Octobe...
|
|
|
|
|
09.09.25 - 07:33
|
4 Analysts Have This To Say About Afya (Benzinga)
|
|
|
Latest Ratings for AFYA
DateFirmActionFromTo Mar 2022UBSMaintainsBuy Jul 2021Morgan StanleyDowngradesOverweightEqual-Weight Apr 2021UBSUpgradesNeutralBuy
View More Analyst Ratings for AFYA
View the Latest Analyst Ratings
read more...
|
|
|
|
|
14.08.25 - 00:06
|
Afya Limited Announces Second-Quarter and First-Half 2025 Financial Results (Business Wire)
|
|
|
Impressive Adjusted EBITDA Margin Expansion and Cash Generation
Full Year 2025 Guidance ReaffirmedBELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and six-month period, which ended June 30, 2025 (second quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS).
Second-Quarter 2025 Highlights
2Q25 Revenue increased 13.5% YoY to R$919.4 million. Revenue excluding acquisitions increased 8.5%, reaching R$879.0 million.
2Q25 Adjusted EBITDA increased 16.6% YoY reaching R$400.8 million, with an Adjusted EBITDA Margin of 43.6%. Adjusted EBITDA Margin increased 110 bps YoY. Adjusted EBITDA excluding acquisitions grew 10.1%, reaching R$378.6 million, with an Adjusted EBITDA Margin of 43.1%.
2Q25 Net Incom...
|
|
|
13.08.25 - 22:51
|
Afya Limited Announces a New Share Repurchase Program (Business Wire)
|
|
|
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today, its Board of Directors has approved a new share repurchase program. Under the share repurchase program, Afya may repurchase up to 4,000,000 of its outstanding Class A common shares, in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning from August 15, 2025 until the earlier of the completion of the repurchase or December 31, 2026, depending upon market conditions.
The share purchases may be made from time to time through open market transactions and are subject to market and business conditions, levels of available liquidity, cash requirements for other purposes, regulatory, and other relevant factors. The share repurchase program will take place in accordance with the conditions established by the Board of Directors on August...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
